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 ￿ ￿
Abstract 
Background 
Prostate cancer is one of the leading causes of cancer illness and death among men in the United 
States and world wide. There is an urgent need to discover good biomarkers for early clinical 
diagnosis and treatment. Previously, we developed an exon-junction microarray-based assay and 
profiled 1532 mRNA splice isoforms from 364 potential prostate cancer related genes in 38 
prostate tissues. Here, we investigate the advantage of using splice isoforms, which couple 
transcriptional and splicing regulation, for cancer classification. 
Results 
As many as 464 splice isoforms from more than 200 genes are differentially regulated in tumors 
at a false discovery rate (FDR) of 0.05. Remarkably, about 30% of genes have isoforms that are 
called significant but do not exhibit differential expression at the overall mRNA level. A support 
vector machine (SVM) classifier trained on 128 signature isoforms can correctly predict 92% of 
the cases, which outperforms the classifier using overall mRNA abundance by about 5%. It is 
also observed that the classification performance can be improved using multivariate variable 
selection methods, which take correlation among variables into account. 
Conclusions 
These results demonstrate that profiling of splice isoforms is able to provide unique and 
important information which cannot be detected by conventional microarrays.   ￿ ￿
Background 
Prostate cancer is the second leading cause of cancer illness and death among men in the United 
States and the third most common cancer world wide [1, 2]. According to recent estimates, it 
accounts for 33% percent of new cancer incidences and six percent of cancer deaths in men world 
wide [2, 3]. In 2002, the number of new incidences and deaths in the United States was 
approximately 189,000 and 30,200, respectively [2]. The difficulty lies, at least partly, in the 
heterogeneous nature of the disease. Tumor growth is initially dependent on androgen levels, 
which stimulate cell proliferation and inhibit apoptosis via the androgen receptor (AR) pathway. 
The prostate-specific antigen (PSA) level has been a standard screening for early diagnosis; 
androgen ablation is a prevalent therapy to repress the development of androgen-dependent 
tumors. However, in many cases, this therapy eventually fails and patients die of the recurrent 
androgen independent prostate cancer (AIPC), a lethal form that progresses and metastasizes (see 
reviews in refs [4, 5]). Multiple pathways permit cancer cells to escape or bypass the control of 
the normal AR activation to up-regulate target genes abnormally [6]. Although it has been 
reported that a number of genes are related to these pathways as well as other aspects of prostate 
cancer, there is still an urgent need for good biomarkers for early clinical diagnosis and treatment. 
Microarray technologies developed in the last decade permit monitoring of mRNA 
abundance levels of tens of thousands of genes in parallel. The accuracy improvement and cost 
reduction have made them a routine approach in looking for genes that are differentially 
expressed between normal and tumor samples or between different tumor types/stages [7-14]. In 
a recent study, Segal et al. summarized ~2000 array experiments and derived a panoramic view 
of activated/deactivated gene expression modules for various types of tumors [15]. 
Microarrays have also been employed in prostate cancer studies. Using cDNA arrays, 
Dhanasekaran et al. measured gene expression in 50 normal and neoplastic prostate specimens, as 
well as three prostate-cancer cell lines, and identified gene signatures characterizing 
androgen-dependent and AIPC samples [16]. Nelson et al. [17] and DePrimo et al. [18] studied ￿ ￿
gene expression in the androgen treated LNCaP cell line, which was known to be highly 
androgen responsive. Lapointe et al. profiled 62 primary tumors and 41 normal specimens; three 
subclasses of tumors representing different tumor stages and risks of recurrence were obtained 
along with characteristic expression signatures [19]. These studies demonstrated the potential of 
using microarray analyses in characterizing prostate cancer at the gene expression level. 
While transcriptional regulation plays important roles within a cell, post-transcriptional 
regulation, such as alternative splicing, dramatically increases the diversity of the proteome. 
Alternative splicing also plays a critical role in gene expression regulation and human diseases 
[20, 21]. It has been reported that about 15% of point mutations that cause human genetic 
diseases can alter splicing patterns [22]. In particular, splicing aberrations have been 
characterized in a number of genes and tumor types (see review by Brinkman [23]).   
In a previous work, we developed a microarray-based assay called RASL
TM (RNA-mediated 
Annealing, Selection, and Ligation), which can systematically monitor the abundances of unique 
splicing events [24]. A modified version of the assay, the DASL
® (cDNA-mediated Annealing, 
Selection, extension and Ligation) assay, offers additional robustness for analyzing highly 
degraded mRNAs, as well as an additional flexibility in probe design [25, 26]. Different from 
other exon-junction arrays [27, 28], the DASL assay achieves high specificity and sensitivity due 
to the fact that both hybridization and ligation of a pair of oligos complementary to the 5’ splice 
site of the upstream exon and the 3’ splice site of the downstream exon are required (see ref [25] 
for details). In our recent study, this technology was applied to profile the abundances of ~1500 
unique splice isoforms in prostate cancer cell lines, tumor specimens and normal control samples 
[29]. This previous study led to two implications: (1) the splicing patterns were altered in a 
number of genes in response to androgen treatment in the LNCaP cell line; (2) a number of splice 
isoforms were differentially expressed in tumor samples. They prioritized a list of prostate cancer 
marker candidates for further investigations. In this study, we extend our previous work and 
perform a comprehensive analysis of using alternatively spliced isoforms to classify prostate 
cancer samples. Compared with our previous work, the focus of this study is to quantitatively ￿ ￿
compare isoform profiling and overall mRNA profiling for cancer classification, which has not 
been systematically investigated before. To be more specific, the contribution of this study lies in 
four key aspects: (1) Isoform-sensitive microarrays studies have been assumed to be able to 
provide more information for cancer classification than conventional microarray studies because 
isoform abundances couple both transcriptional regulation and splicing regulation. However, it 
has remained unclear how much unique information could be provided by isoform profiling. In 
this paper, this assumption is examined qualitatively for the first time through differential 
expression analysis. Further examinations for several genes are also described. (2)    As in a 
number of other microarray studies (e.g. [16, 19]), hierarchical clustering has been used to 
segregate similar tissues. This approach was not able to obtain an unbiased estimation of the 
predictive power for new unknown samples. To assess the predictive power of isoform profiling 
and that of overall mRNA profiling, a support vector machine with recursive feature elimination 
(SVM-RFE) was employed to build prediction models and the prediction accuracies were 
compared. (3) Building a prediction model with a minimal subset of variables is one of the 
critical tasks in cancer classification. We compared two different variable selection methods for 
sample classification and examined whether the robustness of prediction can be improved by 
taking the correlation among isoforms into account during variable selection. (4) In our previous 
study, two smaller datasets generated in different batches were analyzed separately. The two lists 
of candidate markers selected from the two datasets had a relatively small overlap. To achieve 
more robust results, all analyses in this study were based on the larger combined dataset after 
careful normalizations. 
Results 
In our previous work [29], the two datasets of prostate tumors and normal samples were analyzed 
separately by hierarchical clustering because they were generated in two different batches and 
there were significant heterogeneities between them (data not shown). In both datasets, splice 
isoforms could be used to separate tumor samples and normal samples. However, the sample size ￿ ￿
in each dataset was limited and the overlap between the two lists of differentially expressed 
isoforms selected from the two datasets was relatively small. In this paper, the two datasets were 
combined after careful normalizations to achieve more robust results and statistical power (see 
Methods). The combined datasets included 22 cases of prostate tumors and 16 matched normal 
samples. 
Splice isoforms reveal distinct signatures of prostate cancer 
We first examined whether the global distinction between tumors and normal samples still exists 
in the combined dataset by unsupervised methods. As expected, tumors can be readily separated 
from normal samples by average-linkage hierarchical clustering (Figure 1 A and B, cluster C1 
and C2) [30, 31]. Compared with cluster C2, the majority of tissues in cluster C1 are normal 
prostate and stroma, with the average tumor percentage being 8.2% (p<0.0001), and stromal 
percentage being 63.4% (p<0.0001). Of the three tumors segregated with normal samples in 
cluster C1, two have low tumor content. Additional analysis reveals that C2 cases in general have 
a significantly higher percentage of more advanced stages (Stage 3 or above) and more patients 
die of prostate cancer compared to C1 cases. Specifically, 100% of the cases in C1 were from 
patients with organ confined tumors (stage T2), whereas 50% of the cases in C2 were from 
metastasized patients (stage T3 tumors, p<0.001). At the time of analysis, none of the C1 patients 
died of prostate cancer while14% of the C2 patients died of prostate cancer. Interestingly, the 
cluster C2 enriched by tumors was further segregated into two sub-clusters, reflecting different 
percentage in tumor and stromal content (Mean tumor content in sub-cluster C2.1=47.9% v.s. 
C2.2=64.5%, p=0.1; Mean stromal content in C2.1=35.8% v.s. C2.2=20.5, p=0.04).   
Singular value decomposition (SVD) was used to identify an orthogonal low dimensional 
space which preserves the maximal variation of the original high dimensional space. The first two 
principal components capture 17% and 9% of the total variation, respectively (Figure 1F). 
Remarkably, the first principal component alone shows a strong separation of tumor and normal 
samples. The clusters and sub-clusters derived from hierarchical clustering are also reflected in ￿ ￿
the 3D space spanned by the first three principal components (Figure 1G), which confirms the 
results of clustering. 
Further examination of the gene clustering results shows distinct molecular signatures of 
different tissue clusters, including both well known marker genes and less studied marker 
candidates (Figure 1 C, D and E). Figure 1C shows isoforms up-regulated in cluster tumor 
sub-cluster C2.2, including isoforms from genes RPS2, XBP1, U1AF1 and ATP5A1, all of which 
were known to be up-regulated in tumors. Figure 1D shows isoforms down-regulated in normal 
tissues and up-regulated in tumor tissues, including isoforms from genes U2AF2, CLN3 and HPN. 
Figure 1E shows isoforms with high expression levels in normal tissues and down-regulated in 
tumor tissues, especially in sub-cluster C2.2. Several genes in this cluster are known to be 
involved in the TGF-beta signaling pathway, such as TGFB2, LTBP4 and TGFBR3. 
Differentially expressed splice isoforms 
A two sided t-test was used to identify genes with statistically significant changes in expression 
between tumors and normal samples. A false discovery rate (FDR) or q-value was calculated as 
described previously [32], to correct for multiple testing. As a result, 464 isoforms (30%) 
representing 222 genes (61%) are reported as being significant (q-value < 0.05) [see Additional 
file 1]. The high proportion of differentially expressed isoforms reflects the fact that the genes 
profiled are potentially related to prostate cancer according to existing evidence. Top isoforms 
among them include AMACR-2094, FGFR2-0101, FGFR2-0097, FGFR2-0098, CLU-0192, 
PGR-1162, etc. 
Profiling of splice isoforms provides additional information to overall mRNA abundances   
In theory, profiling individual splice isoforms can provide more information than profiling 
overall mRNA levels as in conventional microarrays. This is because isoform profiling detects 
the combinatorial effects of both transcriptional regulation and splicing regulation. Consider the 
simplest case of a gene with two alternatively spliced isoforms. If one isoform is up-regulated in 
tumors whereas the other is down-regulated, the overall mRNA abundance may not change. On 
the contrary, if the overall mRNA level is differentially expressed, there is at least one isoform ￿ ￿
exhibiting differential expression. However, how much additional information can be obtained 
for cancer classification by isoform profiling has not been systematically evaluated. To address 
this question, we compared individual isoforms and overall mRNAs for differential expression.   
Due to the costs and array capacity, the original array design did not include probes targeting 
common regions of all isoforms. Therefore, the overall mRNA expression level can not be 
obtained directly. However, since the probed exon junctions target unique major isoforms and 
hybridization efficiencies of different probes are comparable [25], we reason that the overall 
expression level can be estimated by summing up the abundances of individual isoforms. To 
examine the validity of this idea, two well-known prostate cancer cell lines LnCaP and PC-3 
were profiled using the same DASL assay (splicing array). For comparison, 107 genes were 
arbitrarily selected for gene expression profiling in the same cell lines (expression array). An 
independent oligo pool targeting common regions of all isoforms in each of the 107 genes were 
used in the expression array. Therefore, the log expression ratio of each gene in the two cell lines 
can be obtained from the estimation based on the splicing array and from the direct measurement 
in the expression array independently. To our satisfaction, the two quantities are highly correlated 
(
2 0.80 R = , p=2.2e-16), suggesting a reasonable accuracy of the estimation (Figure 2A).   
Having validated the approach, the overall mRNA abundances of each gene in prostate 
tissues were estimated. A t-test was similarly applied to identify genes with significant 
differential expression in tumors at the overall mRNA level. In total, 159 genes (43.6%) are 
reported as being significant (q-value < 0.05). Again, the high proportion of significant genes 
reflects the fact that they are potentially relevant to prostate cancer according to previous studies. 
Strikingly, more genes are called significant by examining individual isoforms than by examining 
overall mRNAs (222 vs 159, p=0.001, chi-square test). Among the 159 genes that are called 
significant, 150 genes (94%) have at least one isoform that is reported as significant (Figure 2B). 
In contrast, only 68% of genes with significant isoforms can be detected at the overall mRNA 
level. The remaining 32% of the genes have significant isoforms but do not exhibit significant 
differential expression at the overall mRNA level. It is important to note that these genes ￿ ￿
represent the unique information that is provided by splice isoform sensitive microarrays and 
cannot be obtained from conventional microarrays. 
From the perspective of isoforms, 78% of significant isoforms are from those genes that are 
also called significant whereas 22% of significant isoforms are from those genes that do not show 
overall mRNA differential expression (Figure 2D) [see Additional file 2 and 3]. Multiple testing 
has been appropriately accounted for, so the additional significant calls using splice isoforms are 
not due to the different stringencies of thresholds, but reflect additional information provided by 
including splicing regulation. 
For many genes, only one isoform is specifically altered in tumors. In these cases, the 
addition of other isoforms to the total mRNA level simply introduces random noise. Notably, 
there are 14 genes with one isoform being up-regulated in tumors and another isoform being 
down-regulated. Among them, 3 genes are not significant at the overall mRNA level: CD44 
(CD44-1404 vs CD44-1570), ITGB1 (ITGB1-0032 vs ITGB1-0033) and MAPT (MAPT-1060 vs 
MAPT-1061). CD44 is a multifunctional receptor involved in cell-cell interactions and cell 
trafficking. Deregulated expression of a number of variants is correlated with tumor metastasis 
(reviewed by [23]). ITGB1 is a protein involved in extra-cellular matrix interactions and is also 
related to many tumor types, including prostate cancer [22]. 
There are relatively fewer studies discussing the role of MAPT in cancer. MAPT encodes the 
microtubule-associated protein tau mainly expressed in the central nervous system. Mutations in 
the MAPT gene disrupt the normal binding of tau to tubulin. This in turn results in pathological 
deposits of hyperphosphorylated tau in the brain, which is a pathological hallmark of several 
neurodegenerative disorders (see review by Rademakers et al. [33]). Previously, Sangrajrang et al. 
found that MAPT was also expressed in the DU145 cell line using RT-PCR and the expression at 
the protein level was validated by Western blotting [34]. The expression was elevated after 
estramustine treatment and the authors suggested that the protein may be positively related to 
drug resistance. This was consistent with a recent report demonstrating that the up-regulation of 
the protein tau was correlated to the decrease of paclitaxel sensitivity in breast cancer [35]. In our ￿ ￿￿
data, MAPT-1060 (representing the skipping of exon 4A, numbered according to ref [33]) has a   
two fold increase in tumors relative to normal tissues(q-value=0.86%), whereas MAPT-1061 
(representing the inclusion of exon 4A) has a two fold decrease in tumors relative to normal 
tissues (q-value=0.16%). It is likely that exon 4A is uniquely skipped in prostate cancer cells. 
This hypothesis is further supported by the following evidence. Exon 4A harbors a C/T single 
nucleotide polymorphism (SNP) near the 5’ splice site (Entrez SNP: rs17651549, contig position: 
2715394). This SNP was assayed from 71 individuals and the C/T ratio is 0.886/0.114. In the 
major C allele, a putative exonic splicing enhancer (ESE) cagccgg encompassing the SNP is 
predicted by ESEfinder and resembles the specific RNA binding site of SF2/ASF, a critical serine 
rich (SR) protein that helps to recruit the splicing apparatus (score: 4.6, threshold: 1.956) [36]. 
This putative ESE is disrupted in the minor T allele for all four SR proteins in ESEfinder 
including SF2/ASF, SC35, SRp40 and SRp55. However, further experimental studies and 
confirmation of the splicing alteration may be required to validate this hypothesis. 
Profiling of splice isoforms improves predictive power 
A robust prediction model to classify unknown samples is essential for early cancer detection and 
diagnosis. Having demonstrated that a large fraction of genes show differential expression at the 
splice isoform level but not at the overall mRNA level, a key question is how much additional 
predictive power can be achieved by isoform profiling. Another related problem is to select 
minimal subsets of variables with the best performance. Like many other types of tumors, a 
single molecular marker is usually not robust enough for prostate cancer detection, as is the case 
for the widely used PSA level for early stage screening. At the other extreme, including all 
variables from a genome-wide profiling is not justifiable either, due to the noise introduced by a 
huge number of uninformative variables and the difficulty in the interpretation of the resulting 
model.   
A support vector machine (SVM) was used here to build the classifier because of its 
excellent performance in many previous studies with small sample sizes [37]. An recursive ￿ ￿￿
feature elimination (RFE) algorithm was integrated as described previously with minor 
adaptations [38].   
Leave-one-out cross validation (LOOCV) with external variable selection was used to give 
an unbiased evaluation of the prediction accuracy (see Methods for details). SVM-classifiers 
were built using the individual splice isoforms and estimated overall mRNA abundances. The 
results of LOOCV are shown in Figure 3A. For the classifiers using isoform abundances, the best 
performance, 35 correct predictions out of 38 samples (92%), is achieved when 128 isoforms are 
included for classification. For the classifiers using overall mRNA abundances, the best 
performance (87% correct predictions) is achieved when 32 genes are used. The additional 
information provided by splicing regulation gives rise to an improvement of about 5% in 
predictive power. Importantly, the difference persists in the whole range of different sizes of 
selected variable subsets, which is unlikely by random chance. With an independent method, this 
demonstrates that isoform profiling can provide valuable information for cancer classification. 
Also, the classification performance deteriorates when the subset of selected variables is too 
small in size (e.g., 4 variables). This is consistent with the previous observation that a robust 
cancer prediction model should use a reasonable number of molecular signatures [39]. 
Comparison of different variable selection methods 
Both t-tests and SVM-RFE can generate lists of candidate markers. These two approaches 
represent univariate variable selection and multivariate variable selection, respectively. They 
have different assumptions and may characterize different yet overlapping perspectives of the 
molecular mechanisms underlying the data. For example, variables are assumed to be 
independent in a t-test but there is no assumption of independence in SVM-RFE. Comparing the 
multiple outputs of selected signatures by different methods may shed further insights into the 
data and the methods. Therefore, the two different variable selection approaches, t-test and 
SVM-RFE, were applied to select marker candidates and their performances in building linear 
SVM models were compared. The results of LOOCV are shown in Figure 3B. The best 
performance of t-test selection is achieved with a similar number of variables as SVM-RFE. Both ￿ ￿￿
methods result in an accuracy of 92%. The similar best performance by t-test and SVM-RFE is 
likely due to the distinct features of tumors and normal tissues. The information to classify the 
two groups is largely redundant. However, the curve of prediction accuracy by the SVM-RFE 
selection is smoother than that by the t-test selection as the size of selected variable subset 
decreases. This smaller variation suggests that SVM-RFE is more robust than t-test in variable 
selection for cancer classification. 
The 128 isoforms selected by t-test (t-test128 list) and the 128 isoforms selected by 
SVM-RFE (svm128 list) share 42 isoforms (Table 2). The common list includes AMACR-2094, 
AMACR-2097, AMACR-2098, FGFR2-0099, FGFR2-0094, PGR-1166 and PGR-1555 among 
others. They may represent robust marker candidates. Significant isoforms in each list were 
further divided into two groups according to whether the corresponding genes also exhibit 
significant differential expression at the overall mRNA level. Interestingly, among those 86 
isoforms included only in the svm128 list, 13 of the isoforms are in the category that the 
corresponding genes do not show significant differential expression at the overall mRNA level. 
In contrast, among the 86 isoforms included only in the t-test128 list, only 4 isoforms lie in this 
category. Therefore, SVM-RFE captures more information uniquely provided by considering 
splicing regulation (p=0.03, chi-square test). This demonstrates the advantage of a variable 
selection method taking the correlation between variables into account. 
Discussion 
The diagnosis and treatment of prostate cancer are fields with long histories. Various efforts have 
led to the progressive understanding of the disease. However, the present criteria of diagnosis and 
prognosis, as well as the approaches of treatment and surgery, are not sufficiently reliable. 
Previous gene expression profiling studies on prostate tumors and normal tissues demonstrated 
the feasibility in characterizing the molecular alterations at the overall mRNA transcript level. 
However, these transcriptome analyses were based on the old central dogma of “one gene, one 
mRNA”, which may underestimate the complexity of tumorigenesis [23].   ￿ ￿￿
Previously, we carried out a study of prostate cancer by exon-junction microarray-based 
assay and demonstrated the power of this integrated technology in detecting both transcriptional 
and splicing regulation [25, 29]. In this paper, we present systematic analyses with the focus on 
using splice isoform profiling for prostate cancer classification. Isoform-sensitive microarrays 
have been used in several recent studies [24, 25, 27, 29, 40-44] (also see review by Lee and Roy 
[45]). These studies demonstrated that isoform-sensitive microarray is a reliable, high throughput 
approach to detecting splicing alterations in various tissues and conditions. Although more and 
more data are expected to be generated in the near future, the dataset used in this study is the only 
dataset currently available which screened a relatively large sample of cancer and normal tissues. 
As far as we know, this is the first systematic comparison of isoform-sensitive microarrays and 
conventional microarrays for cancer classification. 
Previous studies have used a “splice index”, which is the fraction of each isoform, to remove 
the effect of transcriptional regulation [40, 41]. This is not desired for cancer classification 
because as much information as possible should be incorporated. Therefore the abundance of 
each isoform, which couples both transcriptional regulation and splicing regulation, was used for 
classification. The performance was compared with that of using overall mRNA abundances. One 
has to note a caveat of the current DASL assay: it does not include probes complementary to the 
common regions of all mRNA transcripts for each gene due to the current limit in array capacity. 
Therefore, the overall mRNA level was estimated indirectly by summing up all the isoforms 
targeted. The estimation is not ideal due to the fact that not all isoforms were included in the 
array and the probes target splicing events that are not mutually exclusive in several cases. 
However, the estimation is reasonably good and highly correlated with the direct measurement by 
an expression array. Various other methods were tried to estimate the overall mRNA abundances, 
but the method used here is the most accurate and simplest. 
Among the ~1500 isoforms from putative prostate cancer-related genes, a large fraction of 
them exhibit differential expression in cancer cells. Tumors and normal tissues can be readily 
separated by both unsupervised and supervised methods. By comparing individual isoforms and ￿ ￿￿
overall mRNAs for differential expression, we arrived at the conclusion that an isoform-sensitive 
microarray, which detects coupled transcription and splicing regulation, can provide about 30% 
more information than conventional microarrays. This value may still be underestimated due to 
the following reasons. The current DASL assay included only 364 genes potentially relevant with 
prostate cancer derived from previous studies. Till now, a large body of literature, especially 
those in the genomic scale, focused more on transcriptional regulation. Therefore, the selection of 
genes may be biased to those exhibiting aberrant transcriptional regulation.   
The optimal prediction model was built by SVM with variable selection integrated, a 
powerful machine learning approach. With around 100 isoforms, the best classification 
performance can be achieved at a correct prediction rate of 92%. Compared with the optimal 
SVM classifier built with overall mRNA abundances, this represents an improvement of five 
percent. Therefore, both differential expression analysis and classification analysis quantitatively 
demonstrated the advantage of isoform-sensitive microarrays. 
We also compared the effect of different variable selection approaches on classification 
performance. By taking the correlation between isoforms into account, isoforms selected by 
SVM-RFE are more robust for classification than isoforms selected by a t-test. Although 
univariate two-sample comparisons such as t-test are widely used to identify differentially 
expressed genes, the assumption of independence between genes or isoforms is not biologically 
justifiable. In cancer signal transduction pathways, a group of genes in the same pathway are 
interacting with each other; cross-talks often exist between pathways as well (C Jiang, personal 
communication). Variables are more convoluted in the DASL data due to the coupling of 
transcription and splicing. The multi-loci nature of the disease also makes it difficult to use a 
single or few molecular markers to build a sufficiently robust prediction model. 
This study identified a number of known prostate cancer markers as well as less studied 
marker candidates, which span a wide spectrum of biological functional roles. Some are related 
to signal transduction (SIM2 and CDC42BPA), as well as extracellular matrix and cytoskeleton 
(CD44, MAPT and ILK). Others appear to be involved in epidermal differentiation and ￿ ￿￿
proliferation (KRT15, IGF1, PGR and HPN), cell growth and development (FGFR2), apoptosis 
(DBCCR1 and CLU), lipid metabolism (AMACR), etc. Very significantly, multiple isoforms 
from AMACR, a key player in catalyzing the isomerization of alpha-methyl-branched fatty acid 
and a recently reported good prostate cancer marker, show the strongest signal in our data [46]. 
Several genes encoding splicing factors, such as U2AF1, U2AF2 and DHX34, also show 
significant differential expression. This is consistent with our observation that a large fraction of 
splicing factors are deregulated in tumors (C. Zhang et al, unpublished data). 
Another interesting observation obtained by examining the panel of potential marker 
candidates selected by one or more methods is that a number of genes are normally expressed 
specifically in neuronal cells (such as MAPT, STAC, NELL2, etc). The relationship between 
abnormal expression of neuronal genes and tumors is not completely clear. However, it is 
believed that there is a link between diverse neurodegenerative diseases and cancers via the 
induction of antitumor immunity, known as paraneoplastic neurological degenerations (PND) 
(see review by Albert and Darnell [47]). Alternative splicing is also prevalent for neuronal genes. 
Conclusions 
Profiling of individual isoforms can provide unique and important additional insights into 
prostate cancer classification. Robust prediction models can be built with a subset of isoforms 
selected by multivariate variable selection method. 
Methods 
DASL assay 
The DASL assay and array hybridization were described previously [25]. In contrast to 
conventional microarrays which only measure the overall mRNA abundance of each gene, the 
most distinguishing feature of the DASL assay is that it permits the profiling of each individual ￿ ￿￿
mRNA splice isoform quantitatively. This technology has been shown to be highly sensitive, 
specific and reproducible (R
2 > 0.99 between replicates). 
Tumor and normal tissue profiling 
The array used in this study included 1532 isoforms from 364 genes. These genes, potentially 
related to prostate cancer, were selected from published literature, previous microarray data 
analysis, human genome anatomy projects and EST searching. All of them have known gene 
structures and alternative splicing patterns. Alternatively spliced exon junctions probed in the 
array were obtained by the alignment of mRNA transcripts/ESTs and the genome. They were 
manually annotated and are publicly available from the MAASE database [48, 49]. In total, 22 
cases of archived formalin fixed, paraffin embedded prostate tumors at different tumor stages and 
16 adjacent normal matching samples from the UCSD prostate tumor bank were assayed, each 
with two replicates (Table 1). The detailed information about sample collection, preparation, 
RNA profiling experiment and probe quantification were described elsewhere [29]. The raw data 
is available from the authors upon request. 
Microarray data normalization and statistical analysis 
Before further analysis, a log2 transformation was applied to raw intensities. Since the dataset 
was generated in two batches, heterogeneity between batches has to be removed. As a first step, 
each isoform (row) inside each batch was median-centered separately. Then, the two batches 
were combined and standardized to unit variance across each array (column) and isoform (row) 
as a whole. Finally, the two replicates of each tissue sample were averaged. In this way, each 
value in the data matrix represents the log expression ratio of an isoform in a particular sample 
with respect to a “common control” [15]. The effect of normalization was examined by clustering 
the combined data using real expression values and null control probes, respectively. After 
normalization, there is no visible artificial distinction between the two batches. 
To estimate the overall mRNA abundance of each gene, the intensities of all isoforms were 
summed. Then the same log transformation and normalization steps above were applied. Again, ￿ ￿￿
each normalized value represents the log expression ratio of mRNA abundance in a particular 
sample with respect to a “common control”. 
A two-sided t-test was used to select isoforms or genes with significant differential 
expression between tumors and normal tissues. To correct for the effect of multiple testing, false 
discovery rate (FDR) or q-value was calculated as described previously [32]. 
A chi-square test was used to analyze the significance of frequency data. 
Singular value decomposition 
Singular value decomposition (SVD) is a standard mathematical transformation to find a set of 
orthogonal principal components (PCs) which explain as much variation as possible [50]. The 
power of SVD has been shown in many fields as well as in microarray data analysis. Alter et al. 
and Holter et al. suggested that the first two PCs can characterize cell cycle phases of yeast 
genes[51, 52] . Liu et al. separated prostate and colon tumors from others with the first PC 
alone[53]. In a similar spirit, SVD transformation was used in this study to reveal the “hidden” 
information underlying the original high dimensional dataset. 
SVM-RFE 
A linear support vector machine (SVM) optimizes a linear classifier  ( ) i i D b = + x w x ￿   by 
maximizing the margin of support vectors from two classes, where  i x   is the expression vector 
of a sample  i  and  w   is the vector of weighting coefficient, reflecting the contribution of each 
variable in classification [37]. In the past few years, SVM has been developed and shown as a 
powerful tool for classification problems with a small sample size, such as microarray sample 
classification (e.g. ref [7]). SVM-RFE (RFE stands for recursive feature elimination) is a wrapper 
approach of variable selection, in which the predictive power of a subset of variables is measured 
collectively by the accuracy of the classification based on the subset in consideration [38, 54]. 
Since an exhaustive search of the optimal subset is a combinatorial problem, a heuristic strategy 
must be applied. In SVM-RFE, variables are ranked by the weighting vector  w , by which a 
subset of variables with top ranks is selected. Then the weighting vector  w   is re-evaluated by ￿ ￿￿
optimizing a new classifier with the selected subset and a smaller subset is selected therein. This 
recursive procedure continues until the subset is small enough or the classification performance 
approaches some criteria. In this way, informative variables for classification are recursively 
selected (or uninformative variables are recursively eliminated). Details of the algorithm can be 
found in ref [38]. Our implementation of SVM-RFE used SVMTorch for linear SVM model 
calculations [55]. The default soft margin (C=100) was used. 
Cross validation incorporating variable selection 
Due to the limited sample size, leave-one-out cross validation (LOOCV) was used to evaluate the 
classification performance of SVM classifiers built with subsets of variables selected by t-test and 
SVM-RFE. In each round, one array (test set) is left out to test the classifier trained on the 
remaining arrays (training set). The classification performance is the percentage of correct 
predictions in all rounds. To get an unbiased result, in each round the variable selection step must 
be applied “externally”, i.e. only on the training set, excluding the sample left out for validation 
[39]. Therefore, the subsets of variables selected might be different from round to round. The 
number of times that a variable is selected reflects the robustness of the variable for classification. 
Therefore the final subset of variables can be selected by ordering the number of times that a 
variable is included in the selected subsets of all rounds. 
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Figure legends 
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￿ ￿ ￿ ￿
Figure 1. Prostate tumor and normal samples can be separated into distinct groups.   
(A) A thumbnail overview of the result of the two-way average-linkage hierarchical clustering of 
38 arrays (columns) and 1532 isoforms (rows), as described in ref [30]. (B) Zoom-in view of the 
array clustering dendrogram. The two array clusters, C1 and C2, are enriched by normal samples 
and tumor samples, respectively. Cluster C2 is formed by two sub-clusters, reflecting differences 
in tumor percentage and stroma. (C-E) Isoform signatures up- or down-regulated in different 
array clusters. (F and G) The result of SVD. (F) The percentage of variation (y-axis) captured by 
each principal component (x-axis). (G) The low dimensional projection of arrays in the 3D space 
spanned by the first three principal components. SVD identified the same hierarchical structure as 
revealed by hierarchical clustering. 
 
Figure 2. Profiling splice isoforms provides additional useful information for prostate 
cancer classification.   
(A) The validity of estimating the overall mRNA abundance level from the isoform abundance 
level. The overall mRNA level was estimated by summing up the abundances of individual 
isoforms for each gene. The estimated mRNA abundances of 107 genes were compared with 
direct measurements by an independent expression microarray design (described in main text). 
Plotted are the scatter-plot of log expression ratios of these genes in two prostate cancer cell lines, 
LNCaP and PC-3. These two approaches show good agreement (
2 0.80 R = , p=2.2e-16). (B) 159 
genes out of 364 profiled genes in the DASL assay exhibit differential expression between 
tumors and normal samples at the overall mRNA level (q-value=0.05). Most of them (92%) have 
isoforms with significant differential expression. (C and D) 464 isoforms from 222 genes are 
reported as being differentially expressed between tumors and normal tissues (q-value=0.05), 
which may be prostate cancer marker candidates. 32% of these genes (corresponding to 22% ￿ ￿￿
significant isoforms) do not show differential expression at the overall mRNA level, therefore 
can not be detected by conventional microarrays.   
￿
Figure 3. Prediction models built with linear SVM.   
The performance is measured by leave-one-out cross validation. To get unbiased result, the 
variable selection and training are done in training arrays, which is completely independent with 
the testing array. (A) The comparison in classification performance of SVM-RFE selected 
variables using individual isoforms and the overall mRNAs. (B) The comparison in classification 
performance of variable subsets selected by SVM-RFE and t-test, using individual isoforms. ￿ ￿￿
Tables 
 
￿
Table 1 Pathological information of tumor and normal prostate samples 
ID  Age  Risk group  % tumor  BPH  Atrophy  Stroma  Inflam  PSA  Gleason  Stage 
T5  67  low  50  0  0  20  0  8.48  5+4=9  T3bN1Mx 
T21  74  Low  60  10  10  20  0  6.7  4+4=8  T2bNxMx 
N22  74  Low  0  10  40  50  0  6.7    T2bNxMx 
N30  55  Int  0  10  30  68  0  11.68    T2bN1Mx 
N44  61  low  0  10  2  88  0  5.46    T2cNxMx 
N46  74  High  0  45  20  35  0  8.06    T2aNxMx 
N56  67  High  0  5  0  94  0  5.7    T2aN0Mx 
T72  68  Int  70  0  0  30  0  8.27  4+3=7  T3bN1Mx 
N77  66  Int  0  0  10  89  1  3.15    T2cNxMx 
T78  66  Int  35  5  5  55  0  3.15  3+4=7  T2cNxMx 
T84  60  high  70  5  0  25  0  9.99  4+5=9  T3bN0Mx 
N85  66  Int  0  30  0  70  0  4.37    T3bN0Mx 
T86  66  Int  90  5  0  5  0  4.37  4+4=8  T3bN0Mx 
T87  61  High  25  45  5  25  0  2.23  4+3=7  T2bN0Mx 
N88  61  High  0  10  30  60  0  2.23    T2bN0Mx 
T107  68  Int  60  10  0  30  0  7.4  4+3=7  T2bNxMx 
N109  67  Low  0  5  0  90  5  7    T2bNxMx 
T110  67  Low  40  0  0  58  0  7  3+4=7  T2bNxMx 
N113  70  Low  0  10  5  85  0  4.78    T3aNxMx 
T114  70  Low  40  0  5  55  0  4.78  4+4=8  T3aNxMx 
N121  50    0  30  2  68  0  0.22     
T122  67  Low  70  0  5  25  0  7  3+4=7  T2bNxMx 
T123  78    80  0  0  20  0  17.7  5+5=10  NR 
N133      0  25  5  75  0       
T147  78  Int  70  0  0  30  0  6.9  4+4=8  T2bNoMx 
N148  67  Low  0  35  10  55  0  4.68    T2aNxMx 
N155  70  Int  0  40  10  48  2  8.4    T2cNxMx 
T167  72  Int  80  0  10  10  0  18  4+4=8  T2bNoMx 
T174  83  high  70  5  0  25  0  15  5+4=9  T4 
T177  67  Int  40  0  30  30  0  10.87  4+4=8  T2cNoMx 
T189  77  N/A  70  0  0  0  30  2.51  5+5=10  T2bN2Mx 
T192  61  Int  50  5  10  35  0  5.7  4+4=8  T3aNxMx 
N196  73  low  0  40  5  55  0  4.59    T2bNxMx 
T197  67  high  95  0  0  5  0  21.82  4+4=8  T3aN1Mx 
T198  60    60  0  10  25  0  4.06  4+4=8  T3bNxMx 
N201  64    0  20  5  45  0  UNK    T2bNxMx 
T202  67  Int  90  0  5  5  0  12.34  4+4=8  T3bNxMx 
T204  54  low  80  0  5  15  0  3.91  4+5=9  T3cNxMx 
 ￿ ￿￿
Table 2 Top prostate cancer marker candidates selected by both t-test and SVM-RFE. 
Isoform ID￿ ￿ ￿ ￿  Normalized 
log2 expr 
FDR￿ ￿ ￿ ￿ 
(q-value) 
SVM-RFE 
freq.* 
Protein Name￿ ￿ ￿ ￿ 
ALDH1A2-0004  -1.21  1.3E-04  35  Aldehyde dehydrogenase 1A2 
AMACR-2094  1.41  6.7E-05  38  Alpha-methylacyl-CoA racemase 
AMACR-2097  1.08  9.2E-04  38   
AMACR-2098  0.99  1.8E-03  17   
ANXA2-0914  -1.04  1.8E-03  36  Annexin A2 
APBB3-0185  1.01  1.5E-03  38  Amyloid beta (A4) precursor protein-binding family B member 3 
BC008967-0877  -1.38  7.9E-05  26   
C21ORF5-0239  1.24  6.0E-04  35  Chromosome 21 open reading frame 5 
C7ORF24-0062  1.30  8.4E-05  17   
CALCR-1180  1.05  5.2E-04  37  Calcitonin receptor 
CCT8-0334  1.21  1.5E-04  32  Protein with high similarity to C. elegans Y55F3AR.3 
CDC42BPA-1048  -1.19  6.0E-04  38  CDC42 binding protein kinase alpha 
CDK7-0899  1.35  8.4E-05  37  Cyclin-dependent protein kinase 7 
CES1-0937  -1.34  7.9E-05  32  Cat eye syndrome chromosome region candidate 1 
CLU-0197  -1.11  1.2E-03  38  Clusterin (apolipoprotein J) 
EDNRB-1187  -1.24  4.7E-04  26  Endothelin type B receptor 
FGFR2-0094  -1.13  4.0E-04  19  Fibroblast growth factor receptor 2 
FGFR2-0099  -1.03  7.7E-04  28   
HEBP2-0472  1.08  7.8E-04  24  Heme binding protein 2 (placental protein 23) 
HSPD1-0152  1.10  1.8E-03  37  Chaperonin 60 
HSPD1-0154  1.17  2.8E-04  31   
IGSF4-0722  0.72  2.1E-03  38  Immunoglobulin superfamily member 4 
IMPDH2-0144  1.25  1.3E-04  34  Inosine monophosphate dehydrogenase type 2 
IQGAP2-0234  1.17  5.6E-04  22  IQ motif containing GTPase activating protein 2 
LAMR1-0523  1.20  1.3E-04  38  Laminin receptor 1 
LTBP4-0746  -1.27  1.5E-04  33  Latent transforming growth factor beta binding protein 4 
LTBP4-0748  -1.10  1.4E-03  38   
LYPLA1-0860  1.38  7.9E-05  35  Lysophospholipase 1 
NELL2-0805  -1.10  1.2E-03  24  Nel-like 2 
PGR-1166  -1.16  4.0E-04  32  Progesterone receptor 
PGR-1555  0.85  7.5E-04  38   
PPIB-0969  0.94  2.2E-03  34  Cyclophilin B 
PTS-0059  -1.07  2.2E-03  31  6-pyruvoyltetrahydropterin synthase 
PYCR1-0058  1.28  4.1E-04  38  Pyrroline-5-carboxylate reductase 1 
RING1-0217  -0.93  1.7E-03  22  Ring finger protein 1 
SFRS10-1126  0.95  2.0E-03  34  Splicing factor arginine/serine rich 10 
SMPDL3B-2030  1.09  2.2E-04  38  Protein containing a calcineurin-like phosphoesterase domain 
STAC-1044  -1.31  7.9E-05  34  Src homology three and cysteine rich domain 
TGFB2-0085  -1.11  6.5E-04  38  Transforming growth factor beta 2 
TRIM29-1350  -1.29  1.5E-04  35  Ataxia telangiectasia mutated 
TRIM29-1353  -1.20  1.7E-04  34   
TXNIP-1116  1.09  1.3E-03  38  Thioredoxin interacting protein 
¶ detail information of each isoform, such as the exon junction and probe design, can be accessed at the MAASE database [48]; 
￿￿FDR is calculated using all 38 samples;   
￿ ￿ ￿ ￿SVM-RFE freq.: the number of times that an isoform is included in 38 selected subsets in leave-one-out cross validation. 
 
 
￿￿ ￿￿
Additional files 
Additional file 1. Supplementary table S1. Splice isoforms differentially expressed between 
prostate cancer and normal samples (q-value<0.05). 
Additional file 2. Supplementary table S2. Significant isoforms from those genes that are also 
called significant at overall mRNA level (q-value<0.05). 
Additional file 3. Supplementary table S3. Significant isoforms from those genes that are not 
significant at overall mRNA level (q-value<0.05). 
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Additional files provided with this submission: 
Additional file 3 : BMC_zhang_sup3.xls : 32Kb 
http://www.biomedcentral.com/imedia/1194160364816105/sup3.XLS 
Additional file 2 : BMC_zhang_sup2.xls : 83Kb 
http://www.biomedcentral.com/imedia/1102234911816105/sup2.XLS 
Additional file 1 : BMC_zhang_sup1.xls : 66Kb 
http://www.biomedcentral.com/imedia/8003602588161051/sup1.XLS 